IDEAYA Biosciences, Inc.
General ticker "IDYA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.0B (TTM average)
IDEAYA Biosciences, Inc. follows the US Stock Market performance with the rate: 59.7%.
Estimated limits based on current volatility of 2.9%: low 33.54$, high 35.57$
Factors to consider:
- Total employees count: 131 as of 2024
- Top business risk factors: Limited operating history, Product safety concerns, Regulatory and compliance, Liquidity and credit risks, Early development dependency
- Current price 25.8% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [11.78$, 28.62$]
- 2025-12-31 to 2026-12-31 estimated range: [8.90$, 21.63$]
Financial Metrics affecting the IDYA estimates:
- Negative: with PPE of -7.7 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.95 <= 0.33
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 94.22 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating income (median)
Short-term IDYA quotes
Long-term IDYA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $50.93MM | $23.39MM | $7.00MM |
| Operating Expenses | $113.43MM | $157.81MM | $333.98MM |
| Operating Income | $-62.50MM | $-134.43MM | $-326.98MM |
| Non-Operating Income | $3.85MM | $21.47MM | $52.50MM |
| R&D Expense | $89.54MM | $129.51MM | $294.67MM |
| Income(Loss) | $-58.66MM | $-112.96MM | $-274.48MM |
| Profit(Loss)* | $-58.66MM | $-112.96MM | $-274.48MM |
| Stockholders Equity | $349.45MM | $621.09MM | $1,059.15MM |
| Assets | $387.97MM | $649.32MM | $1,124.09MM |
| Operating Cash Flow | $-87.17MM | $-115.22MM | $-247.58MM |
| Capital expenditure | $3.44MM | $2.37MM | $3.86MM |
| Investing Cash Flow | $-33.40MM | $-158.46MM | $-502.56MM |
| Financing Cash Flow | $97.17MM | $362.72MM | $677.55MM |
| Earnings Per Share** | $-1.42 | $-1.96 | $-3.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.